ASH 2-18

Showing 1 posts of 1 posts found.

gilead-sciences

Gilead’s CAR-T therapy Yescarta shows two-year response duration in large B-cell lymphoma

December 3, 2018
Research and Development, Sales and Marketing ASH 2-18, CAR-T, Cancer, Gilead, Yescarta, leukaemia, pharma

Gilead has gone head to head with Novartis at the American Society of Hematology (ASH) Annual Meeting 2018, meeting the …

The Gateway to Local Adoption Series

Latest content